Previously, we have shown that STAT1/IRF-1 signaling was involved in the development of bevacizumab resistance (often mesenchymal), and that genetic inhibition of IRF1 increased apoptosis in bevacizumab-treated glioma cells [50]. This evidence concerns the gene STAT1 and central nervous system cancer.